



Adbry in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

DERMATOLOGY · ATOPIC DERMATITIS IL-13

The clinical situation

Adbry (tralokinumab; marketed as Adtralza outside the US) is an FDA-approved fully human monoclonal antibody that specifically binds IL-13 and neutralises its interaction with both IL-13 receptor alpha-1 and alpha-2, developed by LEO Pharma. Indicated for moderate-to-severe atopic dermatitis in adults and adolescents inadequately controlled with topical therapies or who have not responded adequately to a previous biologic. Administration is subcutaneous: a loading dose followed by maintenance every two weeks, with an option for every-four-weeks maintenance in selected patients who achieve clear or almost-clear skin at week 16. Adbry's IL-13-specific mechanism is distinct from dupilumab's IL-4Ra blockade, which is relevant in biologic selection.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating dermatologist documents severity, prior therapies, and the clinical case for Adbry over alternatives.
- 2 MoHAP Import License application.** Your dermatologist or the importing pharmacy files the clinical rationale, UAE licence verification, patient reference, product details, and chain-of-custody plan.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under documented chain of custody.
- 4 Cold-chain shipment & arrival.** Temperature-controlled transport; the importer of record receives and hands off per your dermatologist's protocol.
- 5 Initiation & re-supply cadence.** Most patients or caregivers self-inject at home after training; Reserve Meds supports the q2w / q4w maintenance cadence.

Indicative economics

Reference US cash-pay range: USD 3,200–3,800 per month at every-two-weeks maintenance (the q4w schedule reduces monthly cost for eligible responders; Reserve Meds issues a transparent delivered quote at intake).

Indicative first-shipment timing

10–21 days from a complete MoHAP application to first shipment, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Physician documentation kit keyed to MoHAP Drug Department review. **Logistics.** Cold-chain shipment with importer-of-record handling. **Concierge case**

lead. Named point of contact for family and dermatology team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating dermatologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Adbry × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/adbry-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team